BriaCell Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
BriaCell Therapeutics R&D Spending Growth & History (BCTX)
BriaCell Therapeutics's r&d spending was $21.3M for fiscal 2025.
View full BriaCell Therapeutics company overviewBriaCell Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-07-31 | $21.3M | −$5.9M | −21.74% |
| 2024 | 2024-07-31 | $27.2M | $11.8M | +77.21% |
| 2023 | 2023-07-31 | $15.3M | $7.3M | +91.19% |
| 2022 | 2022-07-31 | $8.0M | $6.0M | +296.93% |
| 2021 | 2021-07-31 | $2.0M | −$404,939 | −16.69% |
| 2020 | 2020-07-31 | $2.4M | — | — |
BriaCell Therapeutics quarterly r&d spending
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-04-30 | $6.0M | $1.2M | +24.04% |
| Q2 2026 | 2026-01-31 | $6.1M | $368,912 | +6.49% |
| Q1 2026 | 2025-10-31 | $6.7M | $3.0M | +82.35% |
| Q4 2025 | 2025-07-31 | $7.1M | $2.7M | +61.40% |
| Q3 2025 | 2025-04-30 | $4.8M | −$2.8M | −37.18% |
| Q2 2025 | 2025-01-31 | $5.7M | −$2.6M | −31.16% |
| Q1 2025 | 2024-10-31 | $3.7M | −$3.2M | −46.55% |
| Q4 2024 | 2024-07-31 | $4.4M | −$762,035 | −14.75% |
| Q3 2024 | 2024-04-30 | $7.7M | $3.8M | +98.36% |
| Q2 2024 | 2024-01-31 | $8.3M | $5.2M | +170.44% |
| Q1 2024 | 2023-10-31 | $6.9M | $3.6M | +110.65% |
| Q4 2023 | 2023-07-31 | $5.2M | $2.0M | +63.07% |
| Q3 2023 | 2023-04-30 | $3.9M | $1.6M | +70.16% |
| Q2 2023 | 2023-01-31 | $3.1M | $1.3M | +78.75% |
| Q1 2023 | 2022-10-31 | $3.3M | $2.4M | +271.75% |
| Q4 2022 | 2022-07-31 | $3.2M | — | — |
| Q3 2022 | 2022-04-30 | $2.3M | $1.1M | +101.60% |
| Q2 2022 | 2022-01-31 | $1.7M | $1.5M | +931.56% |
| Q1 2022 | 2021-10-31 | $875,636 | — | — |
| Q3 2021 | 2021-04-30 | $1.1M | — | — |
| Q2 2021 | 2021-01-31 | $165,592 | — | — |
BriaCell Therapeutics r&d spending trends
Over the last five fiscal years, BriaCell Therapeutics's r&d spending increased from $2.4M to $21.3M, a change of $18.8M. The latest reported quarter, Q3 2026, shows $6.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BriaCell Therapeutics source filings ↗